2017
Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid
Castiglioni P, Hartley M, Rossi M, Prevel F, Desponds C, Utzschneider D, Eren R, Zangger H, Brunner L, Collin N, Zehn D, Kuhlmann F, Beverley S, Fasel N, Ronet C. Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid. PLOS Neglected Tropical Diseases 2017, 11: e0005240. PMID: 28099431, PMCID: PMC5242429, DOI: 10.1371/journal.pntd.0005240.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapsid ProteinsFemaleHumansImmunity, CellularLeishmania guyanensisLeishmaniasisLeishmaniavirusMiceMice, Inbred C57BLSymbiosisT-LymphocytesVaccinationConceptsSymptomatic relapseVaccinated miceVaccine strategiesPotent innate immunogenSimilar viral infectionsVirus-related complicationsT-cell transferSpecific T cellsPoor treatment responseLesional inflammationSerum transferT helperInitial treatmentC57BL/6 miceNaïve miceLeishmania infectionPreventive benefitsVaccine opportunitiesT cellsTreatment responseImmune responseViral infectionLesion sizeClinical effortsLeishmania guyanensis
2016
Mammalian Innate Immune Response to a Leishmania-Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence
Eren R, Reverte M, Rossi M, Hartley M, Castiglioni P, Prevel F, Martin R, Desponds C, Lye L, Drexler S, Reith W, Beverley S, Ronet C, Fasel N. Mammalian Innate Immune Response to a Leishmania-Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence. Cell Host & Microbe 2016, 20: 318-328. PMID: 27593513, PMCID: PMC5493041, DOI: 10.1016/j.chom.2016.08.001.Peer-Reviewed Original ResearchConceptsLeishmania RNA virus 1Innate immune responseParasite persistenceImmune responseMiR-155Anti-viral innate immune responsesMacrophage survivalMiR-155-deficient miceTLR-3 activationMiR-155 expressionMammalian host responseMammalian innate immune responseLesional macrophagesParasitic infectionsHost responseDisease severityParasite burdenLeishmania guyanensisPharmacological inhibitionVirus 1Akt phosphorylationAkt activationReduced levelsSurvivalMice
2015
Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse
Bourreau E, Ginouves M, Prévot G, Hartley M, Gangneux J, Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A, Pratlong F, Martin R, Schütz F, Couppié P, Fasel N, Ronet C. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. The Journal Of Infectious Diseases 2015, 213: 105-111. PMID: 26123564, DOI: 10.1093/infdis/jiv355.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiprotozoal AgentsCohort StudiesFemaleHumansLeishmania guyanensisLeishmaniasis, MucocutaneousLeishmaniavirusMalePentamidineRecurrenceTreatment FailureConceptsL. guyanensis infectionLeishmania RNA virus 1American tegumentary leishmaniasisSymptomatic relapseTreatment failureTegumentary leishmaniasisFirst-line treatment failureDoses of pentamidineLeishmania guyanensis infectionLine treatment failureFirst-line treatmentChronic cutaneous leishmaniasisVirus 1Second-line drugsExperimental murine leishmaniasisInflammatory markersHyperinflammatory responseExtended therapyMurine leishmaniasisTherapeutic choiceSuch complicationsRNA virus 1Persistent infectionCutaneous leishmaniasisRelapse